Last reviewed · How we verify
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose)
Pfizer's variant-adapted BNT162b2 (Omicron XBB.1.5) is a 3 microgram dose COVID-19 vaccine marketed by Pfizer Inc. It prevents COVID-19 in individuals 6 months and older, including those who have previously received primary vaccination. The vaccine's mechanism is not explicitly stated on Wikipedia. It has generated $21.2B in revenue. The vaccine's clinical differentiation and pipeline developments are not specified. As a marketed vaccine, it has commercial significance for Pfizer Inc.
At a glance
| Generic name | variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose |
|---|---|
| Sponsor | Pfizer |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of COVID-19 in individuals 6 months of age and older
- Prevention of COVID-19 in individuals 5 years of age and older
- Prevention of COVID-19 in individuals 12 years of age and older
- Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 6 months of age and older who have previously received a booster dose of any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 5 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine
- Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pain medications (e.g., ibuprofen, naproxen)
- Anticoagulants (e.g., heparin, enoxaparin)
- Antiplatelets (e.g., clopidogrel, ticagrelor)
- Thrombolytics (e.g., alteplase, tenecteplase)
- Live vaccines
- Interferon-alpha
- Immunosuppressants (e.g., corticosteroids, cyclosporine)
- Chloroquine
- HIV protease inhibitors
- Ritonavir
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: